| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 110.6MM | +8% |
| Gross Profit | 94.8MM | - |
| Cost Of Revenue | 15.8MM | +12% |
| Operating Income | 41.7MM | -212% |
| Operating Expenses | 53.1MM | - |
| Net Income | 34.8MM | -213% |
| R&D | 2MM | -98% |
| G&A | 42MM | +25% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conferen
Investing in discounted stocks for big gains is a time-tested strategy. Although short-term market fluctuations may capture the attention of many, companies with sustainable growth prospects often prove to be the most lucrative investments over time. Focusing on businesses with competitive advantages, healthy financials and products customers love can position investors to benefit from compounding long-term growth. These companies often have a consistent revenue growth track record and a clear v
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2024 financial results after the market close
Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be...
In this article, we will take a detailed look at Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024. For a quick overview of such stocks, read our article Jim Cramer’s 5 Favorite Healthcare Stock Picks in 2024. Jim Cramer kicked off 2024 with a positive note for the healthcare sector, saying in a program in January that the […]
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome ("LEMS") Awareness Day. This landmark event, now officially observed annually on March 30th
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtual